 | PharmaPoint: Prostate Cancer Canada Drug Forecast and Market Analysis to 2022Oncology◇ 医療 介護 福祉 RCP |
1ListofTablesTable1StageDistributionofProstateCancerbyClassintheUnitedKingdombyDrugClass,201219Figure2CompetitiveAssessmentofLate-StagePipelineAgentsinProstateCancerinSpain-DriversandBarriers,201279Table30ProductProfile-Zometa77Table31ZometaSWOTAnalysis,201219Table4MostCommonlyFollowedTreatmentGuidelinesforProstateCancerbyClassintheUS,201231Table6ProductProfile-Zometa78Table30ProductProfile-Sprycel99Table43SprycelSWOTAnalysis,201279Table31ZometaSWOTAnalysis,201231Table6ProductProfile-CustirsenSodium95Table41CustirsenSodium96Table41CustirsenSodium98Table41CustirsenSodium94Table41CustirsenSodium96Table42ProductProfile-CustirsenSodiumSWOTAnalysis,201235Table8ProductProfile-CustirsenSodium96Table41CustirsenSodium93Table40ProductProfile-Sprycel103Table45YervoySWOTAnalysis,201279Table30ProductProfile-Zometa79Table31ZometaSWOTAnalysis,201235Table8GlobalVariationsinRecommendationsonRoutinePSAScreening16Table3SalesForecasts($m)forXgeva,201219Table4MostCommonlyFollowedTreatmentGuidelinesforProstateCancerMarketinAustralia,201220Figure2CompetitiveAssessmentofLate-StagePipelineAgentsinProstateCancerbyClassintheJapanbyDrugClass,2012-2022126"本商品は、直接お問い合わせください。
また、本サイトで掲載していません。
結果について、いかなる保証も責任も負いかねますので、あらかじめご了承ください。
| PharmaPoint: Prostate Cancer Canada Drug Forecast and Market Analysis to 2022Oncology◇ 医療 介護 福祉 RCP |
次>